Design considerations for artificial pancreas pivotal studies

Diabetes Care

Volumn 39, Issue 7, 2016, Pages 1161-1167

  Russell, Steven J ^a   Beck, Roy W ^b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b JAEB CENTER FOR HEALTH RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN A1C;

ARTIFICIAL PANCREAS; BLOOD GLUCOSE MONITORING; CLINICAL EFFECTIVENESS; CONFERENCE PAPER; EVIDENCE BASED MEDICINE; FOLLOW UP; GLYCEMIC CONTROL; HEALTH CARE SYSTEM; HEALTH INSURANCE; HUMAN; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN INFUSION; INTENTION TO TREAT ANALYSIS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SAFETY; TREATMENT OUTCOME; ADULT; ADVERSE EFFECTS; AGE; AGED; METHODOLOGY; MIDDLE AGED; PATIENT SAFETY; PATIENT SELECTION; PROCEDURES; UTILIZATION; VERY ELDERLY;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; FOLLOW-UP STUDIES; HUMANS; MIDDLE AGED; PANCREAS, ARTIFICIAL; PATIENT SAFETY; PATIENT SELECTION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN;

EID: 84975886219     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc15-2449     Document Type: Conference Paper

References (29)

1. U.S. Food and Drug Administration Center for Devices and Radiological Health. Guidance for Industry and Food and Drug Administration Staff: The Content of Investigational Device Exemption (IDE) and Premarket Approval (PMA) Applications for Artificial Pancreas Device Systems. Rockville, MD, U.S. Department of Health and Human Services, 2012
2. Miller KM, Foster NC, Beck RW, et al.; T1D Exchange Clinic Network. Current state of type 1 diabetes treatment in the U.S.: updated data from the T1D Exchange clinic registry. Diabetes Care 2015;38:971-978
3. Willi SM, Miller KM, DiMeglio LA, et al.; T1D Exchange Clinic Network. Racial-ethnic disparities in management and outcomes among children with type 1 diabetes. Pediatrics 2015;135: 424-434
4. Wong JC, Foster NC, Maahs DM, et al.; T1D Exchange Clinic Network. Real-time continuous glucose monitoring among participants in the T1D Exchange clinic registry. Diabetes Care 2014;37:2702-2709
5. Xing D, Kollman C, Beck RW, et al.; Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group. Optimalsampling intervals to assess long-term glycemic control using continuous glucose monitoring. Diabetes Technol Ther 2011;13:351-358
6. Tamborlane WV, Beck RW, Bode BW, et al.; Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group. Continuous glucose monitoring and intensive treatment of type 1 diabetes. N Engl J Med 2008;359:1464-1476
7. Nathan DM; DCCT/EDIC Research Group. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications study at 30 years: overview. Diabetes Care 2014;37:9-16
8. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977-986
9. Nathan DM, Kuenen J, Borg R, Zheng H, Schoenfeld D, Heine RJ; A1c-Derived Average Glucose Study Group. Translating the A1C assay into estimated average glucose values. Diabetes Care 2008;31:1473-1478
10. Wilson DM, Xing D, Beck RW, et al.; Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group. Hemoglobin A1c and mean glucose in patients with type 1 diabetes: analysis of data from the Juvenile Diabetes Re search Foundation continuous glucose monitoring randomized trial. Diabetes Care 2011;34:540-544
11. Wilson DM, Xing D, Cheng J, et al.; Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group. Persistence of individual variations in glycated hemoglobin: analysis of data from the Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Randomized Trial. Diabetes Care 2011; 34:1315-1317
12. Lachin JM, Genuth S, Nathan DM, Zinman B, Rutledge BN; DCCT/EDIC Research Group. Effect of glycemic exposure on the risk of microvascu-lar complications in the Diabetes Control and Complications Trial-revisited. Diabetes 2008; 57:995-1001
13. The Diabetes Control and Complications Trial Research Group. The relationship of glyce-mic exposure (HbA1c) to the risk of development and progression of retinopathy in the Diabetes Control and Complications Trial. Diabetes 1995;44:968-983
14. Nordwall M, Abrahamsson M, Dhir M, Fredrikson M, Ludvigsson J, Arnqvist HJ. Impact of HbA1c, followed from onset of type 1 diabetes, on the development of severe retinopathy and nephropathy: the VISS Study (Vascular Diabetic Complications in Southeast Sweden). Diabetes Care 2015;38:308-315
15. Beck R, Steffes M, Xing D, et al.; Diabetes Research in Children Network (DirecNet) Study Group. The interrelationships of glycemic control measures: HbA1c, glycated albumin, fruc-tosamine, 1, 5-anhydroglucitrol, and continuous glucose monitoring. Pediatr Diabetes 2011;12: 690-695
16. Nathan DM, McGee P, Steffes MW, Lachin JM; DCCT/EDIC Research Group. Relationship of glycated albumin to blood glucose and HbA1c values and to retinopathy, nephropathy, and cardiovascular outcomes in the DCCT/EDIC study. Diabetes 2014;63:282-290
17. Battelino T, Phillip M, Bratina N, Nimri R, Oskarsson P, Bolinder J. Effect of continuous glucose monitoring on hypoglycemia in type 1 diabetes. Diabetes Care 2011;34:795-800
18. Beck RW, Hirsch IB, Laffel L, et al.; Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group. The effect of continuous glucose monitoring in well-controlled type 1 diabetes. Diabetes Care 2009; 32:1378-1383
19. Kollman C, Calhoun P, Lum J, Sauer W, Beck RW. Evaluation of stochastic adjustment for glucose sensor bias during closed-loop insulin delivery. Diabetes Technol Ther 2014;16:186-192
20. Beck RW, Calhoun P, Kollman C. Use of continuous glucose monitoring as an outcome measure in clinical trials. Diabetes Technol Ther 2012;14:877-882
21. Fox LA, Beck RW, Xing D; Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group. Variation of interstitial glucose measurements assessed by continuous glucose monitors in healthy, nondiabetic individuals. Diabetes Care 2010;33:1297-1299
22. Fiallo-Scharer R, Cheng J, Beck RW, et al.; Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group. Factors predictive of severe hypoglycemia in type 1 diabetes: analysis from the Juvenile Diabetes Research Foundation continuous glucose monitoring randomized control trial dataset. Diabetes Care 2011;34:586-590
23. Frier BM. Hypoglycaemia in diabetes melli-tus: epidemiology and clinical implications. Nat Rev Endocrinol 2014;10:711-722
24. Sanon VP, Sanon S, Kanakia R, et al. Hypo-glycemia from a cardiologist's perspective. Clin Cardiol 2014;37:499-504
25. Brod M, Christensen T, Bushnell DM. The impact of non-severe hypoglycemic events on daytime function and diabetes management among adults with type 1 and type 2 diabetes. J Med Econ 2012;15:869-877
26. Brod M, Christensen T, Thomsen TL, Bushnell DM. The impact of non-severe hypo-glycemic events on work productivity and diabetes management. Value Health 2011;14: 665-671
27. Brod M, Pohlman B, Wolden M, Christensen T. Non-severe nocturnal hypoglycemic events: experience and impacts on patient functioning and well-being. Qual Life Res 2013;22:997-1004
28. Beck RW, Kollman C, Xing D, Buckingham BA, Chase HP. Outcome measures for outpatient hypoglycemia prevention studies. J Diabetes Sci Technol 2011;5:999-1004
29. Rodbard D. Interpretation of continuous glucose monitoring data: glycemic variability and quality of glycemic control. Diabetes Tech-nol Ther 2009;11(Suppl. 1):S55-S67